# Gelijktijdige griep- en RSV-vaccinatie bij hoogrisico hartfalenpatiënten

*geplaatst 2025-12-01 · Hartfalen · ESC heart failure · doi 10.1002/ehf2.15432 · https://hartvaat.nl/2025/12/01/gelijktijdige-griep-en-rsv-vaccinatie-bij-hoogrisico-hartfalenpatienten/*

Studie onderzocht de haalbaarheid en veiligheid van gelijktijdige griep- en RSV-vaccinatie bij hartfalenpatiënten. De co-vaccinatie was veilig en effectief, wat de vaccinatiegraad kan verhogen.

## English: Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients.

A prospective randomised study evaluated simultaneous influenza and RSV vaccination in high-risk heart failure patients. The co-vaccination strategy was safe and effective, potentially improving vaccine uptake in this vulnerable population.

## Abstract (original, from the publication)

BACKGROUND: There is a scarcity of prospective data on the impact of available vaccinations against respiratory viruses on hard clinical endpoints in patients with heart failure (HF). AIMS: We investigated whether, in the population of high-risk HF patients, simultaneous vaccination against influenza and respiratory syncytial virus (RSV) improves outcomes during the subsequent infection season. METHODS: We conducted a prospective, randomized, single-centre, open-label study in which patients with high-risk HF were randomized 1:1 to simultaneous influenza and RSV vaccination or standard of care (SOC). The primary composite endpoint comprised all-cause death, HF hospitalization (HFH) or clinical signs/symptoms of infection within a 6 month follow-up period (regular structured telephone interview). Secondary endpoints were components of the composite primary endpoint. RESULTS: Two hundred twenty patients were randomized. During the follow-up period, the primary endpoint occurred in 59% of patients in the vaccination group versus 75% in the SOC group [hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.48-0.92, P = 0.01]. Regarding the secondary endpoint analyses, during 6 month follow-up, 3% in the vaccination group died compared with 5% of patients in the SOC arm (HR 0.50, 95% CI 0.12 1.99, P = 0.32), and 18% versus 16% of study participants were hospitalized for HF in the two study arms, respectively (HR 0.86, 95% CI 0.45-1.62, P = 0.64). Infection occurred in 53% of vaccinated patients compared with 68% in SOC (HR 0.68, 95% CI 0.48-0.96, P = 0.03). CONCLUSIONS: In the population of high-risk HF, simultaneous vaccination against influenza and RSV reduced the incidence of the primary outcome. The effect was driven by a significant reduction in infections.

Auteurs: Jan Biegus, Leszek Szenborn, Michał Tkaczyszyn, Robert Zymlinski, Gad Cotter, Michał Zakliczynski, Krzysztof Reczuch, Mateusz Guzik, Szymon Urban, Marta Rosiek-Biegus, Berenika Jankowiak, Gracjan Iwanek, Marta Wleklik, Marat Fudim, Piotr Ponikowski

---
Bron: ESC heart failure, https://doi.org/10.1002/ehf2.15432. Bijgewerkt 2026-07-03T13:31:00Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.